The most frequent chromosomal translocations in pediatric acute myeloid leukemia affect the 11q23 locus and give rise to mixed lineage leukemia (MLL) fusion genes, MLL-AF9 being the most prevalent. The MLL-AF9 fusion gene has been shown to induce leukemia in both mouse and human models. In this study, we demonstrate that leukemogenic activity of MLL-AF9 requires RUVBL2 (RuvB-like 2), an AAA þ ATPase family member that functions in a wide range of cellular processes, including chromatin remodeling and transcriptional regulation. Expression of RUVBL2 was dependent on MLL-AF9, as it increased upon immortalization of human cord blood-derived hematopoietic progenitor cells with the fusion gene and decreased following loss of fusion gene expression in conditionally immortalized mouse cells. Short hairpin RNA-mediated silencing experiments demonstrated that both the immortalized human cells and the MLL-AF9-expressing human leukemia cell line THP-1 required RUVBL2 expression for proliferation and survival. Furthermore, inhibition of RUVBL2 expression in THP-1 cells led to reduced telomerase activity and clonogenic potential. These data were confirmed with a dominant-negative Walker B-mutated RUVBL2 construct. Taken together, these data suggest the possibility of targeting RUVBL2 as a potential therapeutic strategy for MLL-AF9-associated leukemia.
INTRODUCTION
The mixed lineage leukemia (MLL) gene is frequently rearranged in childhood acute myeloid leukemia (AML). Chromosomal translocations affecting the MLL locus give rise to oncogenic fusion genes that encode chimeric transcription factors. These have been shown to impose aberrant transcriptional programmes in normal hematopoietic stem and hematopoietic progenitor cells (HPC), leading to transformation and leukemogenesis. [1] [2] [3] Sustained expression of MLL-fusions is essential for maintenance of HPC immortalization [4] [5] [6] and progression of leukemia. 3, 7 The oncogenicity of MLL-fusions appears to depend on their transcriptional regulation of core self-renewal and differentiation pathways. [8] [9] [10] Recent experiments demonstrated that the transcription factor MYB is a critical mediator of MLL-fusion-induced self-renewal. 3, 11 This suggests that targeting pathways downstream of MYB activity may offer a therapeutic opportunity for MLL-rearranged AML. In this context, it is interesting to note that a recent study used global gene expression analysis to identify a number of genes positively regulated by both the MLL-AF9 fusion and by MYB. 3 One of these was the Ruvbl2 (RuvB-like 2, also known as Reptin) gene. These data are consistent with a previous study demonstrating that overexpression of Hoxa9 and Meis1, key transcriptional targets of MLL-fusions, 4, 5 resulted in increased expression of both Myb and Ruvbl2.
11 RUVBL2 is a member of the adenosine triphosphatases associated with diverse cellular activities (AAA þ ) family and functions as part of multi-protein complexes in chromatin remodeling, DNA repair, regulation of transcription and ribonucleoprotein assembly. 12 It is required for multiple processes necessary for the survival and growth of normal cells and organisms. 12 Evidence also exists that it may have a critical role in cancer. It is overexpressed in hepatocellular carcinoma, 13, 14 breast cancer 15 and renal carcinoma, 16 in comparison to normal surrounding tissue. Furthermore, RUVBL2 overexpression was shown to result in enhanced tumorigenicity, 14 whereas its silencing inhibited tumor growth and viability in vitro 14, 16 and in tumor xenografts. 17 These data suggest that RUVBL2 is a key mediator of oncogenesis.
In the study presented here, we confirm that the loss of MLL-AF9 in conditionally immortalized mouse myeloid cells results in decreased expression of the RUVBL2 protein and demonstrate that immortalization of human cord blood-derived HPC with MLL-AF9 leads to increased RUVBL2 gene expression. Furthermore, knock down of RUVBL2 expression inhibits the proliferation, survival and clonogenic potential of MLL-AF9-expressing human leukemia cells, and results in reduced telomerase activity. Taken together, these data suggest that RUVBL2 represents a novel therapeutic target in MLL-rearranged AML.
MATERIALS AND METHODS Mice
All mice were maintained in the animal facilities of the UCL Institute of Child Health, London, and experiments were performed according to the United Kingdom Home Office regulations and UCL Institute of Child Health institutional guidelines.
Retroviral and lentiviral vectors and virus production
Retroviral vectors for the conditonal expression of MLL-AF9 were generated as follows. The 3 0 MLL-ENL fragment, downstream of the BamHI restriction enzyme site in the MLL cDNA, was removed from the pMSCVneo-TRE-MLL-ENL vector 7 and replaced with the 3 0 MLL-AF9 fragment, downstream of the MLL BamHI site in the MLL-AF9 cDNA (kindly provided by D.C. Tkachuk, Toronto, Canada). 18 Retroviral supernatants were produced as described previously. 7 The UMG-LV6 (V6) lentiviral vector (Chiarella et al. in preparation) was generated from the FUGW vector, 19 by replacing the UbiC promoter-EGFP (enhanced green fluorescent protein) cDNA cassette with a dual promoter cassette where the transgene expression is driven by the UbiC promoter and that of EGFP by the À 170/ þ 33 WASP (Wiskott-Aldrich syndrome protein) promoter. 20 The UMG-LV6MA (V6MA) vector was constructed by inserting the MLL-AF9 cDNA in the XbaI and BamHI sites downstream of the UbiC promoter. Short hairpin RNAs (shRNAs; non-silencing control (RHS4346), RUVBL2.3 (V3LHS_641741), RUVBL2.5 (V3LHS_375236)) from the Open Biosystems Human GIPZ shRNAmir lentiviral library (Open Biosystems/Thermo Scientific, Lafayette, CO, USA) were cloned into the pSFFV-GIPZ or pSFFV-GIPZ-hCD2T vectors. pSFFV-GIPZ was constructed by replacing the CMV promoter of the pGIPZ vector (Open Biosystems/Thermo Scientific) with the SFFV promoter from the pCSGW vector. 21 The pSFFV-GIPZ-hCD2T vector was made by replacing the tGFP cDNA in pSFFV-GIPZ with a cDNA encoding the human 'tailless' CD2 molecule. 22 Lentiviral MISSION shRNA constructs targeting MYC (Clone ID: NM_002467.2-1377s1c1 (shMYC.1) and NM_002467.2-1377s1c2 (shMYC.2)) and MYB (Clone ID: NM_005375.2-1099s21c1 (shMYB.1) and NM_005375.2-927s21c1 (shMYB.2)) and nonsilencing control (SHC002) were purchased from Sigma-Aldrich, Dorset, UK. The dominant-negative RUVBL2 mutant was generated by introducing a G to A bp point mutation, encoding a D299N amino-acid substitution within the conserved RUVBL2 Walker B sequence, 23 using the QuikChange SiteDirected Mutagenesis Kit (Agilent Technologies, Berkshire, UK) with a RUVBL2 cDNA containing IMAGE clone (Source BioScience, Nottingham, UK). The mutant cDNA was cloned into the pSFFV-GIPZ vector, replacing the tGFP cDNA. The 293FT packaging cells (Invitrogen, Life Technologies, Paisley, UK) were transiently co-transfected with the lentiviral expression vectors, the pCMV-PAX2 construct and either the pVSV-G (kind gifts of D. Trono, Lausanne, Switzerland) or the pCMV-RD114 (kind gift of Y. Takeuchi, London, UK) envelope constructs.
Purification and transduction of human and mouse cells
Conditionally immortalized MLL-AF9 mouse myeloid cells were generated using the same strategy as that used for the conditional MLL-ENL cells. 7 Briefly, C57BL/6 lineage-negative bone marrow HPC were co-transduced with the pMSCV-neo-TRE-MLL-AF9 and pMSCV-tTA-IRES-EGFP retroviral constructs, and conditional cell lines isolated after three rounds of plating in methocult M3434 (Stem Cell Technologies, Manchester, UK). Cell lines were maintained in RPMI-1640 (Invitrogen, Life Technologies) with 10% heat-inactivated fetal calf serum (Invitrogen, Life Technologies), 100 U/ml Penicillin (Invitrogen, Life Technologies), 100 mg/ml Streptomycin (Invitrogen, Life Technologies), 2 mM L-glutamine (Invitrogen, Life Technologies) and 50 mM 2-mercaptoethanol (Sigma-Aldrich) supplemented with 100 ng/ml SCF (stem-cell factor), 10 ng/ml interleukin (IL)-3 and 10 ng/ml IL-6 (all from Peprotech, London, UK). In some cases, cells were treated with 2 mg/ml doxycycline (Takara Bio Europe/Clontech, Saint Germain-en-Laye, France) or 10 ng/ml G-CSF (granulocyte colonystimulating factor; Peprotech). Frozen human cord blood mononuclear cells were purchased from Stem Cell Technologies. CD34 þ cells were enriched from thawed human cord blood mononuclear cells by magneticactivated cell sorting using the human CD34 microbead kit (Miltenyi Biotec, Surrey, UK), according to the manufacturer's instructions (resulting in 90, 21 and 62% CD34 þ cells from cord blood samples 1, 2 and 3, respectively). Enriched CD34 þ cells were maintained in hematopoietic progenitor growth medium (Lonza, Verviers, Belgium), supplemented with 100 ng/ml rhSCF (recombinant human SCF), 100 ng/ml rhTPO (recombinant human thrombopoietin) and 100 ng/ml rhFLT3L (all from Miltenyi Biotec), and were transduced four times, serially, with UMG-LV6 or UMG-LV6MA on a retronectin-(Takara Bio) coated plate. The resulting V6 and V6MA cells were cultured in Iscove's Modified Dulbecco's Medium (Invitrogen, Life Technologies) with 20% heat-inactivated fetal calf serum, 100 U/ml Penicillin, 100 mg/ml Streptomycin and 2 mM L-glutamine, supplemented with 100 ng/ml rhSCF, 100 ng/ml rhTPO, 100 ng/ml rhFLT3L, 10 ng/ml rhIL-3 and 10 ng/ml rhIL-6 (all from Miltenyi Biotec). THP-1 cells (DSMZ, Braunschweig, Germany) were cultured in RPMI-1640, supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml Penicillin, 100 mg/ml Streptomycin and 2 mM L-glutamine. V6MA and THP-1 cells were transduced with lentiviral supernatant by spinoculation at 700 g, 25 1C for 45 min in the presence of 5 mg/ml polybrene. Transduced cells were used for experiments or placed in puromycin selection 48 h after transduction. For all experiments in which transduced cells were selected, this was performed for 3 days using 1 mg/ml (V6MA) or 2 mg/ml (THP-1) puromycin. Following puromycin selection, live cells were enriched using the Dead Cell Removal Kit (Miltenyi Biotec), and equivalent numbers of live cells were plated out into control and experimental cultures. Equivalent cell numbers from each culture were then replated every 3-4 days.
MTS Proliferation assay
Following transduction with shRNA constructs, cells were cultured for 72 h. CellTiter 96 Aq ueous One Solution Reagent (Promega, Southampton, UK) was added to each well and proliferation determined by measuring the absorbance at 490 nm using a 550 BioRad plate-reader (Bio-Rad, Hertfordshire, UK).
Colony-formation assay
In all, 1 Â 10 4 THP-1 cells were resuspended in 0.6 ml of cell resuspension solution (R&D Systems, Abingdon, UK) and added to 2.7 ml of human methylcellulose base media (R&D Systems). The cells were cultured for 14 days before evaluation of colony number and staining with 1 mg/ml p-iodonitrotetrazolium (Sigma-Aldrich).
Apoptosis and cell-cycle assays
Apoptosis was detected using the Annexin V Apoptosis detection kit (eBioscience; Hatfield, UK). Cell-cycle analysis was performed using the Click-iT EdU Flow Cytometry Assay Kit (Invitrogen, Life Technologies).
Flow cytometry
Cells were resuspended in phosphate-buffered saline 0.5% bovine serum albumin and 0.05% sodium azide, and human cells were preincubated with human FcR-binding inhibitor (eBioscience) before staining with allophycocyanin conjugated antibody to human CD15 (Biolegend, London, UK). Mouse cells were stained with antibodies to mouse c-Kit and Gr-1 (eBioscience). Cells were analyzed on an LSRII (BD Bioscience, San Jose, CA, USA), and the data were analyzed with Summit 4.3 software (Beckman Coulter, High Wycombe, UK).
Telomerase assay
Telomerase activity was measured using the Telo TAGGG Telomerase PCR ELISAplus kit (Roche Diagnostics, West Sussex, UK) according to the manufacturer's protocol. Total protein was extracted from 2 Â 10 5 cells, and lysate equivalent to 1 Â 10 3 cells was used per assay. Color change was measured using a Model 680 microplate reader (Bio-Rad) at 450 nm, with a reference wavelength of 690 nm.
Western blot analysis
Cells were lysed in reducing sample buffer (100 mM dithiothreitol, 2% w/v sodium dodecyl sulfate, 10% v/v Glycerol, 0.002% w/v bromophenol blue, 62.5 mM Tris-HCL). Unless otherwise stated, protein samples were resolved on a 10% polyacrylamide gel and transferred onto a PVDF membrane (Millipore; Hertfordshire, UK). Western blots were stained with antibodies against RUVBL2 (42), HSP90 (F-8) and Clathrin heavy chain (Clone TD.1) (all from Santa Cruz Biotechnology, Heidelberg, Germany) and against MLL (Clone N4.4; Millipore). Proteins were detected using appropriate secondary horseradish peroxidise-conjugated antibodies and visualized using a chemiluminescence reagent (GE Healthcare, Buckinghamshire, UK).
Real-time quantitative PCR
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen, Sussex, UK) according to the manufacturer's instructions. RNA was converted into cDNA using a cDNA synthesis kit (Invitrogen, Life Technologies) according to the manufacturer's instructions. Samples were treated with DNase I (Invitrogen, Life Technologies) before reverse transcription using the Moloney murine leukemia virus reverse transcriptase (Invitrogen, Life Technologies). Quantitative reverse transcriptase-PCR was performed on isolated mRNA using TaqMan probe-based chemistry and an ABI Prism RUVBL2 function in MLL-AF9 leukemia H Osaki et al 7900HT fast Sequence Detection System (Applied Biosystems, Life Technologies, Paisley, UK). All primer/probe sets were from Applied Biosystems, Life Technologies.
RESULTS

RUVBL2 expression is maintained by MLL-AF9
RUVBL2 protein was readily detected in conditionally immortalized MLL-AF9 mouse myeloid cells (Figure 1a) . In order to establish whether MLL-AF9 was required to maintain RUVBL2 expression, these cells were treated with doxycycline to turn off fusion gene expression. 6 Loss of MLL-AF9 expression in these cells results in differentiation (Supplementary Figure S1) , as previously demonstrated for conditionally immortalized MLL-ENL cells. 6 For this reason, cells were treated in parallel with G-CSF, which induces myeloid differentiation without affecting MLL-fusion expression.
6 RUVBL2 protein was almost completely lost following 72 h of doxycycline treatment, G-CSF causing significantly less reduction in RUVBL2 expression (Figure 1a) . These data indicate that reduced RUVBL2 expression following treatment of cells with doxycycline is due to loss of MLL-AF9 expression rather than myeloid differentiation per se. To determine whether RUVBL2 expression was also associated with MLL-AF9 transformation in human cells, human cord blood-derived CD34 Figure S3) , key transcriptional targets and/or downstream mediators of MLLfusion activity, were all upregulated in V6MA cells in comparison to empty vector-transduced (V6) HPC. RUVBL2 mRNA levels were also found to be significantly higher in V6MA cells compared with that in empty vector control V6 cells (Figure 1b) . Although modest, these data are in line with the increases in RUVBL2 mRNA expression previously reported in cancer versus normal tissue. 14 These results are consistent with the data from the immortalized mouse cells and suggest that MLL-AF9 maintains expression of the RUVBL2 gene. Previous studies in mouse MLL-AF9 cells suggest that this is likely to be via induction of the transcription factor MYB. 3 We confirmed this in human leukemia cells, by demonstrating reduced RUVBL2 expression upon MYB silencing in MLL-AF9-expressing THP-1 cells transduced with two independent MYB shRNAs ( Figure 1c) . By contrast, silencing MYC did not have a comparable effect on RUVBL2 expression (Supplementary Figure S4) , despite MYC being implicated in the transcriptional regulation of RUVBL2 expression. [24] [25] [26] Blocking RUVBL2 expression and function inhibits proliferation and survival of human leukemia cells As RUVBL2 expression appears to be regulated by MLL-AF9 in both the mouse and human MLL-AF9-immortalized cells, it is possible that this gene has a role in leukemogenesis. The importance of RUVBL2 in human leukemic cells was examined by analyzing the effect of shRNA-mediated knock down of RUVBL2 gene expression. To eliminate the possibility of off-target effects, two independent shRNAs against RUVBL2 (RUVBL2.3 and RUVBL2.5) were used for this experiment. Both shRNAs were found to be effective at inhibiting RUVBL2 protein expression (Figure 2a ), resulting in a marked decrease in proliferation of THP-1 cells in liquid culture (Figure 2b ). THP-1 cells were also transduced with a dominant-negative RUVBL2 (D299N) expression vector. RUVBL2 (D299N) contains a point mutation within the conserved Walker B motif that abolishes its ability to hydrolyze ATP and bind DNA. 23 Expression of the RUVBL2 (D299N) mutant caused a similar inhibition of THP-1 proliferation to that observed with the RUVBL2.3 shRNA construct (Figure 2c ). These data suggest that RUVBL2 expression is essential for THP-1 cell proliferation.
In order to identify the mechanisms responsible for the reduced THP-1 proliferation, cell cycle, differentiation and apoptosis analyses were then performed. A decrease in the percentage of THP-1 cells entering into the S-phase of the cell cycle was observed following transduction with RUVBL2.3 shRNA or RUVBL2 (D299N)-expressing lentiviral constructs (Figures 3a and b) . Both RUVBL2.3 and RUVBL2.5 shRNAs caused a uniform increase in the mean fluorescence of CD15 in transduced THP-1 cells, normally associated with differentiation ( Figure 3c ). Furthermore, both shRNA and mutant constructs induced a significant increase in THP-1 cell apoptosis (Figure 3d ). These results indicate that the loss of RUVBL2 expression, or function, inhibits THP-1 cell proliferation due to reduced cell-cycle progression, increased differentiation and apoptosis. Interestingly, the RUVBL2 (D299N) mutant was more potent than either RUVBL2 shRNA constructs at inducing growth arrest and apoptosis (Figures 3a, b and d) . This likely reflects the incomplete silencing of RUVBL2 by the shRNA constructs used and suggest that they underestimate the consequences of losing expression of this molecule.
The effect of inhibiting RUVBL2 expression in V6MA cells was then addressed. Transduction of V6MA cells with either the RUVBL2.3 shRNA or mutant constructs caused a similar inhibition in proliferation (Figure 4a, Supplementary Figure S5 ) to that observed with THP-1 cells. Furthermore, the RUVBL2.3 shRNA caused significantly less inhibition of proliferation in CD34 þ human cord blood cells (Figure 4b ). Both shRNA and mutant constructs also caused an increase in V6MA cell apoptosis Figure 4c ). It is important to note that the V6MA cells in this experiment were used after the time point at which the corresponding control V6 cells had stopped proliferating. This allowed us to assess the importance of RUVBL2 for MLL-AF9 function in these cells. These data suggest that RUVBL2 expression is essential for the proliferation and survival of immortalized human MLL-AF9 cells, as well as that of human leukemia cells. RUVBL2 expression is required for telomerase activity in THP-1 cells One of the essential roles of RUVBL2 is to function as a component of the telomerase complex, required for its assembly. 27 Consistent with these data, silencing of RUVBL2 expression in gastric and cervical cancer cell lines was shown to reduce telomerase activity. 28 High levels of telomerase activity have previously been demonstrated in human cord blood-derived MLL-AF9 cells, but it was not clear whether this activity was dependent on MLL-AF9 function. 29 However, the possibility remains that MLL-AF9 may be responsible for inducing telomerase activity indirectly, by upregulating RUVBL2 expression. In order to examine this, telomerase reverse transcriptase (TERT) mRNA expression was measured in V6MA and control V6 cells. Both of the V6MA cell lines analyzed were indeed found to express significantly higher levels of TERT mRNA than the V6 controls (Figure 5a ). The consequences of inhibiting RUVBL2 expression on telomerase activity were then examined in THP-1 cells (Figure 5b ). Telomerase activity was readily detectable in THP-1 cells and was significantly reduced following transduction with either RUVBL2.3 or RUVBL2.5 shRNAs, compared with that in THP-1 cells transduced with control shRNA. These results indicate that the RUVBL2 expression is required for the maintenance of telomerase activity in THP-1 cells.
RUVBL2 expression is required in order to maintain the clonogenic potential of THP-1 cells Loss of RUVBL2 was previously shown to affect the clonogenic potential of gastric cancer cells. 28 In the present study, inhibition of RUVBL2 expression and function were found to block proliferation and induce apoptosis of both THP-1 and V6MA cells (see above). Methylcellulose colony-formation assays were performed in order to examine what effect this would have on self-renewal of THP-1 cells. THP-1 cells transduced with RUVBL2 shRNA or RUVBL2 (D299N) mutant constructs were transferred into methylcellulose and colony formation was measured after 14 days. Transduction of THP-1 cells with either RUVBL2.3 or RUVBL2.5 shRNAs reduced the number of colonies formed, compared with that of control shRNA cells (Figures 6a and b) . In addition, a reduction in colony formation was also evident for THP-1 cells transduced with RUVBL2 (D299N) (Figures 6c and d) . Thus, expression of functional RUVBL2 is essential in order to maintain the clonogenic potential of THP-1 cells. In order to determine whether the requirement for RUVBL2 is limited to MLL-rearranged AML cells, a panel of AML cell lines were then transduced with RUVBL2.3 shRNA (Figure 7) . In all the cell lines tested, silencing RUVBL2 resulted in loss of cells from culture. This is consistent with the overexpression of RUVBL2 mRNA in all the AML cells lines in comparison to normal CD34 þ human cord blood cells (Supplementary Figure S6) . Thus, taken together our data indicate that AML cells in general require elevated expression levels of RUVBL2 for growth and survival. In MLL-AF9 leukemia cells, this is ensured by induction of the transcription factor MYB. This suggests that RUVBL2 represents a candidate therapeutic target in AML.
DISCUSSION
In this paper, we have presented data suggesting that RUVBL2 is a key regulator of MLL-AF9-induced transformation and leukemia. The data suggest that RUVBL2 has a critical role in at least three of the hallmarks of cancer, as recently defined. 30 It is required in order for MLL-AF9 to sustain the hyperproliferative state and RUVBL2 function in MLL-AF9 leukemia H Osaki et al clonogenic potential of leukemia cells and to confer resistance to the induction of cell death. Furthermore, RUVBL2 has a critical role in ensuring replicative immortality of leukemic cells, by positively regulating telomerase activity. Finally, RUVBL2 is required for proliferation of AML cells in general and thus represents a candidate target for future therapies of this disease. RUVBL2 functions in numerous normal cellular processes in protein complexes together with its related member of the AAA þ ATPase family, RUVBL1.
12,31 However, RUVBL2 and RUVBL1 have also been implicated in transformation and malignancy. For example, the oncogenic transcription factor MYC can bind both RUVBL2 and RUVBL1 proteins, the latter being specifically required for its transforming activity. 24 Both RUVBL2 and RUVBL1 proteins also impact on the ability of MYC to stimulate cell-cycle progression by potentiating its inhibition of the transcription factor Miz1 and consequently the transcriptional repression of the p21 CIP1 gene. 32 They have also been demonstrated to enhance Miz1/Max-dependent repression of the CCAAT/enhancer-binding protein d tumor-suppressor gene by MYC. 33 Despite the high primary amino-acid sequence homology of RUVBL1 and RUVBL2, they can also function antagonistically or indeed independently of one another in cancer. Thus, both proteins can bind b-catenin, but whereas RUVBL1 enhances transcriptional activation of Wnt target genes, RUVBL2 represses them. 31 In addition to these antagonistic activities, evidence suggests that RUVBL2 may also function in distinct recently described repressive b-catenin complexes, 34 together with co-repressors such as TLE1 (transducin-like enhancer of split 1) and histone deacetylases. 35, 36 The function of RUVBL2 and RUVBL1 proteins in MYC and b-catenin activities is highly relevant to the data reported in the present study, given the central roles played by these transcription factors in MLLrearranged leukemia. [37] [38] [39] [40] [41] In particular, the growth inhibition, differentiation and apoptosis of MLL-AF9-expressing human leukemic cells upon RUVBL2 inhibition, by shRNA-mediated knockdown or dominant-negative RUVBL2 (D299N) expression, is consistent with the pro-oncogenic effects of both RUVBL2 and RUVBL1 proteins on MYC function. 12 One of the targets co-operatively regulated by RUVBL2 and MYC was recently demonstrated to be the TERT gene. 28 The TERT protein, encoded by the TERT gene, forms the catalytic core of telomerase, together with the telomerase RNA component. Telomerase is responsible for the synthesis of telomeric DNA repeats. Telomeres function to protect eukaryotic chromosome ends from damage and their progressive shortening during proliferation is thought to limit the replication potential of normal cells. 42, 43 By contrast, maintenance of telomere length is a key feature of immortal cellular replication, and elevated telomerase activity is associated with most spontaneous human cancers. 44 Recent experiments in human cells have also linked transformation by MLL-fusions to increased telomerase activity. 29, 45 Thus, immortalization of human cord blood-derived HPC by MLL-AF9 was accompanied by reactivation of telomerase, 29 while knock down of MLL-AF4 in human acute lymphoblastic leukemia cell lines resulted in decreased telomerase activity. 45 Furthermore, in addition to transcriptional regulation of TERT, RUVBL2, together with RUVBL1, was shown to be essential for temolerase holoenzyme assembly. 27 Our data are consistent with RUVBL2 regulating telomerase activity in human MLL-AF9 leukemia cells. Inhibition of telomerase activity presents an additional dimension to the anti-leukemic consequences of RUVBL2 targeting, potentially synergizing with the effects on proliferation, viability and clonogenicity. In the context of leukemia therapy, cancer cells escaping the immediate effects of RUVBL2 inhibition would become vulnerable to telomere attrition and a consequent loss of viability.
Previous studies indicate that MLL-fusions maintain elevated levels of RUVBL2 gene expression indirectly. Thus, transcription factor MYB is induced by MLL-fusion proteins and has been shown to have an essential role in mediating their downstream leukemogenic activity in the mouse models. 3, 11 Myb silencing was found to abrogate transformation by MLL-fusion genes and leukemia progression. Furthermore, Myb knock down resulted in decreased expression of a number of target genes, among them Ruvbl2. 3, 11 In human THP-1 cells, MYB knock down was also found to reduce RUVBL2 expression. 46 On the other hand, several studies have suggested that RUVBL2 is a transcriptional target of MYC. [24] [25] [26] Our data suggest that RUVBL2 expression in THP-1 cells is indeed maintained by MYB, with little or no evidence for its control by MYC. Taken together, these data indicate that MLL-fusions induce the expression of MYB, which, in turn, activates RUVBL2 transcription.
Our data demonstrate that induction of RUVBL2 is required for MLL-AF9 oncogenicity. However, analysis of an AML cell panel, both MLL-rearranged and non-MLL-rearranged, demonstrated that all AML cell lines examined exhibited elevated RUVBL2 expression and were dependent upon RUVBL2 for growth and survival. It is possible that increased expression of RUVBL2 is required for myeloid transformation, different oncogenes potentially using different mechanisms to achieve this. This is consistent with evidence for RUVBL2 function in a number of different cancers. [13] [14] [15] [16] [17] Although RUVBL2 is known to have important roles Figure 7 . RUVBL2 is required for human AML cell growth. Graphs showing the percentage of (a) GFP þ MLL-rearranged and (b) non-MLLrearranged AML cells, at indicated time points in liquid culture, after transduction with control shRNA (Co) and RUVBL2.3 shRNA (R3) pSFFV-GIPZ lentiviral vectors. In this vector, tGFP is expressed from the same mRNA as the shRNA, and tGFP expression was used to identify transduced cells. 
